Literature DB >> 1972165

Production of TNF-alpha and TNF-beta by staphylococcal enterotoxin A activated human T cells.

H Fischer1, M Dohlsten, U Andersson, G Hedlund, P Ericsson, J Hansson, H O Sjögren.   

Abstract

Staphylococcal enterotoxin at concentrations of less than 1 pg/ml induces significant TNF activity in human peripheral blood T cells and monocytes. Maximal TNF activity is routinely detected after 48 to 72 h of culture. IL-2 and IL-4 were both growth promoting for human T cells but only IL-2 could efficiently induce TNF production. The production of TNF-alpha and TNF-beta differed greatly in kinetics. An early intracytoplasmatic production of TNF-alpha after 6 h was detected in both monocytes and T cells whereas a late production of TNF-beta (lymphotoxin) after 48 h, occurred in the T cell population. Induction of TNF-alpha and TNF-beta production by Staphylococcal enterotoxin requires the presence of both monocytes and T cells. The CD4+45R- but not CD4+45R+ and CD8+ cells supported TNF-alpha production in monocytes. The main lytic component from Staphylococcal enterotoxin-activated mononuclear cells is TNF-beta. CD4+ and CD8+ T cells produced about equal amounts of biologically active TNF into the culture supernatants but a fourfold higher frequency of TNF-beta producing cells was demonstrated among CD4+ vs CD8+ cells. The CD4+45R- T cell subset was an efficient producer of TNF-beta and IFN-gamma whereas the CD4+45R+ T cell subset produced significant amounts of TNF-beta but only marginal amounts of IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972165

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

Review 1.  Immune response to staphylococcal superantigens.

Authors:  T Krakauer
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Staphylococcal exotoxins stimulate nitric oxide-dependent murine macrophage tumoricidal activity.

Authors:  D J Fast; B J Shannon; M J Herriott; M J Kennedy; J A Rummage; R W Leu
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

Review 3.  Genetically engineered superantigens in experimental tumor therapy.

Authors:  P Antonsson; J Hansson; T Kalland; P A Lando; L Ohlsson; E Schad; A Svensson; M Dohlsten
Journal:  Springer Semin Immunopathol       Date:  1996

4.  Overexpression of the T-cell receptor V beta 3 in transgenic mice increases mortality during infection by enterotoxin A-producing Staphylococcus aureus.

Authors:  Y X Zhao; A Abdelnour; T Kalland; A Tarkowski
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

5.  Construction and characterization of a novel fusion protein MG7-scFv/SEB against gastric cancer.

Authors:  Qiang Tong; Ke Liu; Xiao-Ming Lu; Xiao-Gang Shu; Guo-Bin Wang
Journal:  J Biomed Biotechnol       Date:  2010-03-22

6.  Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.

Authors:  M Dohlsten; G Hedlund; E Akerblom; P A Lando; T Kalland
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

7.  A novel approach for cancer immunotherapy: tumor cells with anchored superantigen SEA generate effective antitumor immunity.

Authors:  Wenxue Ma; Hai Yu; Qingqing Wang; Hongchuan Jin; Joyce Solheim; Vinod Labhasetwar
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

8.  Immunotherapy of human colon cancer by antibody-targeted superantigens.

Authors:  M Dohlsten; P A Lando; P Björk; L Abrahmsén; L Ohlsson; P Lind; T Kalland
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

9.  Combined activation of murine lymphocytes with staphylococcal enterotoxin and interleukin-2 results in additive cytotoxic activity.

Authors:  H Belfrage; P Bhiladvala; G Hedlund; M Dohlsten; T Kalland
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

10.  Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice.

Authors:  M Dohlsten; M Björklund; A Sundstedt; G Hedlund; D Samson; T Kalland
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.